Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| Pfizer Inc. (NYSE: PFE) | Delayed: 29.79 -0.32 (1.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.11 | 52 Week High | $37.39 | |||
| Open | $30.00 | 52 Week Low | $28.25 | |||
| Day High | $30.09 | P/E | 18.05 | |||
| Day Low | $29.76 | EPS | $1.65 | |||
| Volume | 5,516,813 | |||||
